

JACIE Cumulative Outcomes Report

2025 Annual Report - Rolling Cohort Analysis

HSCT Program Quality Indicators

2026-01-23

 AI-Generated Report with Rolling Cohort Methodology

Executive Summary

Reporting Period and Methodology

Reporting Period: Calendar Year 2025 (January 1 - December 31, 2025)

Methodology: Cumulative Rolling Cohort Analysis following JACIE Italian guidelines

Cumulative Rolling Cohort Methodology

This report uses **cumulative rolling cohort analysis** as specified by JACIE Italy. For each quarter and timepoint, we calculate outcomes for ALL patients who reached that milestone during the cumulative period from Q1 through that quarter.

Key principle: Results should be **cumulative and monotonically increasing** - the percentage at 100 days should be 30 days, and 365 days should be 100 days, since we're looking at the same patients plus those who reach later milestones.

Example for Q4 2025:

- **30-day outcome:** All patients whose 30-day milestone fell between **Jan 1 - Nov 30, 2025** (transplanted Sep 1, 2024 - Oct 31, 2025)
- **100-day outcome:** All patients whose 100-day milestone fell between **Jan 1 - Sep 30, 2025** (transplanted Jul 1, 2024 - Sep 30, 2025)
- **365-day outcome:** All patients whose 365-day milestone fell between **Jan 1 (2024) - Dec 31, 2025** (transplanted Jan 1, 2024 - Dec 31, 2025)

This provides mature outcome data since patients have had sufficient follow-up time.

Key Findings Summary

Overall Mortality (All Patients) - Cumulative Rolling Cohort

Table 1: Overall Cumulative Mortality - Rolling Cohort Analysis

Timepoint	Cohort Size	Deaths	Mortality Rate
30 days	30	0	0% (0/30)
100 days	29	1	3.4% (1/29)
365 days	20	7	35% (7/20)

Understanding Cohort Sizes

Note that cohort sizes **differ** across timepoints because each represents a different observation period:

- **30-day cohort:** Patients whose 30-day milestone occurred Jan 1 - Nov 30, 2025 (N = 30)
- **100-day cohort:** Patients whose 100-day milestone occurred Jan 1 - Sep 30, 2025 (N = 29)
- **365-day cohort:** Patients whose 365-day milestone occurred Jan 1, 2024 - Dec 31, 2025 (N = 20)

The mortality percentages are cumulative and should generally increase at later timepoints (30d 100d 365d) as cumulative mortality accrues over time.

Mortality by Cause: TRM, NRM, and RRM

Table 2: Cumulative Mortality Breakdown by Cause (Overall = TRM + NRM + RRM)

Timepoint	Overall Mortality	TRM	NRM	RRM
30 days	0% (0/30)	0% (0/30)	0% (0/30)	0% (0/30)
100 days	3.4% (1/29)	0% (0/29)	3.4% (1/29)	0% (0/29)
365 days	35% (7/20)	15% (3/20)	10% (2/20)	10% (2/20)

Understanding Mortality Categories

TRM (Treatment-Related Mortality) includes deaths directly related to the transplant procedure and immediate complications.

NRM (Non-Relapse Mortality) includes deaths from:

- Infection
- GVHD complications
- Organ toxicity
- Other transplant-related complications (not classified as TRM)

RRM (Relapse-Related Mortality) includes deaths from disease progression or relapse.

At 365 days: **TRM = 15%**, **NRM = 10%**, and **RRM = 10%**


Detailed Results

1. Overall Mortality Analysis

1.1 Mortality at Key Timepoints by Cause

Figure 1: Cumulative Mortality Outcomes by Timepoint

Cumulative Rolling Cohort Analysis – 2025 (TRM, NRM, RRM)



1.2 Mortality by Disease Status at Transplant

Table 3: Cumulative Mortality by Disease Status at HSCT

Group	Timepoint	Cohort Size	Deaths	Mortality Rate
Complete Remission				
Complete Remission	30 days	23	0	0% (0/23)
Complete Remission	100 days	16	0	0% (0/16)
Complete Remission	365 days	11	2	18.2% (2/11)
Not in Complete Remission				
Not in Complete Remission	30 days	7	0	0% (0/7)
Not in Complete Remission	100 days	13	1	7.7% (1/13)
Not in Complete Remission	365 days	9	5	55.6% (5/9)

Disease Status Impact

Complete Remission patients: 365-day mortality = 18.2%

Not in Complete Remission: 365-day mortality = 55.6%

Achieving complete remission before transplant is associated with better outcomes.

2. Non-Relapse Mortality (NRM)

2.1 NRM by Timepoint

Table 4: Cumulative Non-Relapse Mortality (NRM)

Timepoint	Cohort Size	NRM Events	NRM Rate
30 days	30	0	0% (0/30)
100 days	29	1	3.4% (1/29)
365 days	20	2	10% (2/20)

NRM Analysis

Definition: NRM represents deaths from transplant-related complications, NOT disease progression.

- **30-day NRM:** 0% - Early transplant complications
- **100-day NRM:** 3.4% - Standard early NRM window
- **365-day NRM:** 10% - Cumulative NRM including late complications

NRM accounts for **29%** of all deaths at 365 days.

2.2 NRM by Disease Status

Table 5: Non-Relapse Mortality by Disease Status

Group	Timepoint	Cohort Size	NRM Events	NRM Rate
Overall				
Overall	30 days	30	0	0% (0/30)
Overall	100 days	29	1	3.4% (1/29)
Overall	365 days	20	2	10% (2/20)
Complete Remission				
Complete Remission	30 days	23	0	0% (0/23)
Complete Remission	100 days	16	0	0% (0/16)
Complete Remission	365 days	11	1	9.1% (1/11)
Not in Complete Remission				
Not in Complete Remission	30 days	7	0	0% (0/7)
Not in Complete Remission	100 days	13	1	7.7% (1/13)
Not in Complete Remission	365 days	9	1	11.1% (1/9)

2.3 NRM Causes Breakdown

Table 6: Table 6: Breakdown of NRM by Specific Cause (365-day cohort)

Cause of NRM	N Events	Percentage
Other	2	2 (100%)

2.4 TRM (Treatment-Related Mortality)

2.4.1 TRM by Timepoint

Table 7: Table 6A: Cumulative Treatment-Related Mortality (TRM)

Timepoint	Cohort Size	TRM Events	TRM Rate
30 days	30	0	0% (0/30)
100 days	29	0	0% (0/29)
365 days	20	3	15% (3/20)

TRM Analysis

Definition: TRM represents deaths specifically from treatment-related complications (distinct from NRM and relapse).

- **30-day TRM:** 0%
- **100-day TRM:** 0%
- **365-day TRM:** 15%

TRM accounts for **43%** of all deaths at 365 days.

2.4.2 TRM by Disease Status

Table 8: Table 6B: Treatment-Related Mortality by Disease Status

Group	Timepoint	Cohort Size	TRM Events	TRM Rate
Overall				
Overall	30 days	30	0	0% (0/30)
Overall	100 days	29	0	0% (0/29)
Overall	365 days	20	3	15% (3/20)
Complete Remission				
Complete Remission	30 days	23	0	0% (0/23)
Complete Remission	100 days	16	0	0% (0/16)
Complete Remission	365 days	11	1	9.1% (1/11)
Not in Complete Remission				
Not in Complete Remission	30 days	7	0	0% (0/7)
Not in Complete Remission	100 days	13	0	0% (0/13)
Not in Complete Remission	365 days	9	2	22.2% (2/9)

3. Relapse-Related Mortality (RRM)

Table 9: Table 7: Cumulative Relapse-Related Mortality (RRM)

Timepoint	Cohort Size	RRM Deaths	RRM Rate
30 days	30	0	0% (0/30)
100 days	29	0	0% (0/29)
365 days	20	2	10% (2/20)

3.1 RRM by Disease Status

Table 10: Table 8: Relapse-Related Mortality (RRM) by Disease Status

Group	Timepoint	Cohort Size	RRM Deaths	RRM Rate
Overall				
Overall	30 days	30	0	0% (0/30)
Overall	100 days	29	0	0% (0/29)
Overall	365 days	20	2	10% (2/20)
Complete Remission				
Complete Remission	30 days	23	0	0% (0/23)
Complete Remission	100 days	16	0	0% (0/16)
Complete Remission	365 days	11	0	0% (0/11)
Not in Complete Remission				
Not in Complete Remission	30 days	7	0	0% (0/7)
Not in Complete Remission	100 days	13	0	0% (0/13)
Not in Complete Remission	365 days	9	2	22.2% (2/9)

RRM Summary

- **365-day RRM:** 10%
- RRM accounts for **29%** of all deaths at 365 days
- Not in CR patients show higher RRM (22.2%) vs CR patients (0%)

Late Relapse Deaths (After 365 Days)

Important Note: The 365-day rolling cohort includes ** 20 patients** whose 365-day milestone fell during the reporting period. Of these:


- ** 2 patients** died from relapse **within 365 days** post-HSCT (included in 365-day RRM rate above)
- ** 1 additional patient(s)** died from relapse **after 365 days** post-HSCT:
 - Patient GF60: Death at day **428** (63 days after 365-day milestone)

These late deaths are correctly EXCLUDED from the 365-day mortality analysis as they occurred beyond the 365-day timepoint. They would be captured in longer-term follow-up analyses (e.g., 2-year or 3-year mortality).

row_spec(1, bold = TRUE, background = "#9B59B6", color = "white") “

Figure 2: Acute GVHD Grade II-IV by Donor Type

Cumulative incidence at 100 days post-HSCT (Cumulative Rolling Cohort)



4.2 Chronic GVHD (365 days)

Table 11: Table 10: Chronic GVHD Cumulative Incidence (365 days)

Severity	Cohort Size	Events	Cumulative Incidence
Any	20	2	10% (2/20)
Moderate-Severe	20	1	5% (1/20)

5. Comprehensive Outcomes by Donor Type

Table 12: Table 11: Comprehensive Outcomes by Donor Type

Donor Type	365-Day Mortality	NRM at 365 Days	Acute GVHD II-IV
Sibling HLA-identical	0% (0/2)	0% (0/2)	0% (0/3)
Haploidentical	50% (6/12)	16.7% (2/12)	33.3% (4/12)
MUD	20% (1/5)	0% (0/5)	9.1% (1/11)
MMUD	0% (0/1)	0% (0/1)	33.3% (1/3)

6. Mortality Outcomes by Donor Type

6.1 Overall Mortality by Donor Type (All Timepoints)

Table 13: Overall Mortality by Donor Type Across All Timepoints

Donor Type	Timepoint	Cohort Size	Deaths	Mortality Rate
Sibling HLA-identical				
Sibling HLA-identical	30 days	3	0	0% (0/3)
Sibling HLA-identical	100 days	3	0	0% (0/3)
Sibling HLA-identical	365 days	2	0	0% (0/2)
Haploidentical				
Haploidentical	30 days	9	0	0% (0/9)
Haploidentical	100 days	12	1	8.3% (1/12)
Haploidentical	365 days	12	6	50% (6/12)
MUD				
MUD	30 days	12	0	0% (0/12)
MUD	100 days	11	0	0% (0/11)
MUD	365 days	5	1	20% (1/5)
MMUD	30 days	6	0	0% (0/6)
MMUD	100 days	3	0	0% (0/3)
MMUD	365 days	1	0	0% (0/1)

6.2 NRM by Donor Type (All Timepoints)

Table 14: Non-Relapse Mortality by Donor Type Across All Timepoints

Donor Type	Timepoint	Cohort Size	NRM Events	NRM Rate
Sibling HLA-identical				
Sibling HLA-identical	30 days	3	0	0% (0/3)
Sibling HLA-identical	100 days	3	0	0% (0/3)
Sibling HLA-identical	365 days	2	0	0% (0/2)
Haploidentical				
Haploidentical	30 days	9	0	0% (0/9)
Haploidentical	100 days	12	1	8.3% (1/12)
Haploidentical	365 days	12	2	16.7% (2/12)
MUD				
MUD	30 days	12	0	0% (0/12)
MUD	100 days	11	0	0% (0/11)
MUD	365 days	5	0	0% (0/5)
MMUD	30 days	6	0	0% (0/6)
MMUD	100 days	3	0	0% (0/3)
MMUD	365 days	1	0	0% (0/1)

6.3 Relapse Mortality by Donor Type (All Timepoints)

Table 15: Relapse Mortality by Donor Type Across All Timepoints

Donor Type	Timepoint	Cohort Size	Relapse Deaths	Relapse Rate
Sibling HLA-identical				
Sibling HLA-identical	30 days	3	0	0% (0/3)
Sibling HLA-identical	100 days	3	0	0% (0/3)
Sibling HLA-identical	365 days	2	0	0% (0/2)
Haploidentical				
Haploidentical	30 days	9	0	0% (0/9)
Haploidentical	100 days	12	0	0% (0/12)
Haploidentical	365 days	12	1	8.3% (1/12)
MUD				
MUD	30 days	12	0	0% (0/12)
MUD	100 days	11	0	0% (0/11)
MUD	365 days	5	1	20% (1/5)
MMUD	30 days	6	0	0% (0/6)
MMUD	100 days	3	0	0% (0/3)
MMUD	365 days	1	0	0% (0/1)

6.4 TRM by Donor Type (All Timepoints)

Table 16: Table 15A: Treatment-Related Mortality by Donor Type Across All Timepoints

Donor Type	Timepoint	Cohort Size	TRM Events	TRM Rate
Sibling HLA-identical				
Sibling HLA-identical	30 days	3	0	0% (0/3)
Sibling HLA-identical	100 days	3	0	0% (0/3)
Sibling HLA-identical	365 days	2	0	0% (0/2)
Haploidentical				
Haploidentical	30 days	9	0	0% (0/9)
Haploidentical	100 days	12	0	0% (0/12)
Haploidentical	365 days	12	3	25% (3/12)
MUD				
MUD	30 days	12	0	0% (0/12)
MUD	100 days	11	0	0% (0/11)
MUD	365 days	5	0	0% (0/5)
MMUD	30 days	6	0	0% (0/6)
MMUD	100 days	3	0	0% (0/3)
MMUD	365 days	1	0	0% (0/1)

7. Combined Stratification: Donor Type × Disease Status

7.1 Overall Mortality by Donor Type and CR Status (All Timepoints)

Table 17: Table 16: Overall Mortality by Donor Type and Disease Status (30, 100, 365 days)

CR Status	Donor Type	Timepoint	N	Deaths	Mortality Rate (n/N)
Complete Remission	Sibling HLA-identical	30 days	1	0	0% (0/1)
Complete Remission	Sibling HLA-identical	100 days	1	0	0% (0/1)
Complete Remission	Sibling HLA-identical	365 days	2	0	0% (0/2)
Complete Remission	Haploidentical	30 days	7	0	0% (0/7)
Complete Remission	Haploidentical	100 days	5	0	0% (0/5)
Complete Remission	Haploidentical	365 days	5	2	40% (2/5)
Complete Remission	MUD	30 days	10	0	0% (0/10)
Complete Remission	MUD	100 days	8	0	0% (0/8)
Complete Remission	MUD	365 days	3	0	0% (0/3)
Complete Remission	MMUD	30 days	5	0	0% (0/5)
Complete Remission	MMUD	100 days	2	0	0% (0/2)
Complete Remission	MMUD	365 days	1	0	0% (0/1)
Not in Complete Remission	Sibling HLA-identical	30 days	2	0	0% (0/2)
Not in Complete Remission	Sibling HLA-identical	100 days	2	0	0% (0/2)
Not in Complete Remission	Sibling HLA-identical	365 days	0	NA	NA% (NA/0)
Not in Complete Remission	Haploidentical	30 days	2	0	0% (0/2)
Not in Complete Remission	Haploidentical	100 days	7	1	14.3% (1/7)
Not in Complete Remission	Haploidentical	365 days	7	4	57.1% (4/7)
Not in Complete Remission	MUD	30 days	2	0	0% (0/2)
Not in Complete Remission	MUD	100 days	3	0	0% (0/3)
Not in Complete Remission	MUD	365 days	2	1	50% (1/2)
Not in Complete Remission	MMUD	30 days	1	0	0% (0/1)
Not in Complete Remission	MMUD	100 days	1	0	0% (0/1)
Not in Complete Remission	MMUD	365 days	0	NA	NA% (NA/0)

7.2 NRM by Donor Type and CR Status (All Timepoints)

Table 18: Table 17: NRM by Donor Type and Disease Status (30, 100, 365 days)

CR Status	Donor Type	Timepoint	N	NRM Events	NRM Rate (n)
Complete Remission	Sibling HLA-identical	30 days	1	0	0% (0/1)
Complete Remission	Sibling HLA-identical	100 days	1	0	0% (0/1)
Complete Remission	Sibling HLA-identical	365 days	2	0	0% (0/2)
Complete Remission	Haploidentical	30 days	7	0	0% (0/7)
Complete Remission	Haploidentical	100 days	5	0	0% (0/5)
Complete Remission	Haploidentical	365 days	5	1	20% (1/5)
Complete Remission	MUD	30 days	10	0	0% (0/10)
Complete Remission	MUD	100 days	8	0	0% (0/8)
Complete Remission	MUD	365 days	3	0	0% (0/3)
Complete Remission	MMUD	30 days	5	0	0% (0/5)
Complete Remission	MMUD	100 days	2	0	0% (0/2)
Complete Remission	MMUD	365 days	1	0	0% (0/1)
Not in Complete Remission	Sibling HLA-identical	30 days	2	0	0% (0/2)
Not in Complete Remission	Sibling HLA-identical	100 days	2	0	0% (0/2)
Not in Complete Remission	Sibling HLA-identical	365 days	0		NA NA% (NA/0)
Not in Complete Remission	Haploidentical	30 days	2	0	0% (0/2)
Not in Complete Remission	Haploidentical	100 days	7	1	14.3% (1/7)
Not in Complete Remission	Haploidentical	365 days	7	1	14.3% (1/7)
Not in Complete Remission	MUD	30 days	2	0	0% (0/2)
Not in Complete Remission	MUD	100 days	3	0	0% (0/3)
Not in Complete Remission	MUD	365 days	2	0	0% (0/2)
Not in Complete Remission	MMUD	30 days	1	0	0% (0/1)
Not in Complete Remission	MMUD	100 days	1	0	0% (0/1)
Not in Complete Remission	MMUD	365 days	0		NA NA% (NA/0)

7.3 Relapse Mortality by Donor Type and CR Status (All Timepoints)

Table 19: Table 18: Relapse Mortality by Donor Type and Disease Status (30, 100, 365 days)

CR Status	Donor Type	Timepoint	N	Relapse Deaths	Relapse Rate
Complete Remission	Sibling HLA-identical	30 days	1	0	0% (0/1)
Complete Remission	Sibling HLA-identical	100 days	1	0	0% (0/1)
Complete Remission	Sibling HLA-identical	365 days	2	0	0% (0/2)
Complete Remission	Haploidentical	30 days	7	0	0% (0/7)
Complete Remission	Haploidentical	100 days	5	0	0% (0/5)
Complete Remission	Haploidentical	365 days	5	0	0% (0/5)
Complete Remission	MUD	30 days	10	0	0% (0/10)
Complete Remission	MUD	100 days	8	0	0% (0/8)
Complete Remission	MUD	365 days	3	0	0% (0/3)
Complete Remission	MMUD	30 days	5	0	0% (0/5)
Complete Remission	MMUD	100 days	2	0	0% (0/2)
Complete Remission	MMUD	365 days	1	0	0% (0/1)
Not in Complete Remission	Sibling HLA-identical	30 days	2	0	0% (0/2)
Not in Complete Remission	Sibling HLA-identical	100 days	2	0	0% (0/2)
Not in Complete Remission	Sibling HLA-identical	365 days	0	NA	NA% (NA/0)
Not in Complete Remission	Haploidentical	30 days	2	0	0% (0/2)
Not in Complete Remission	Haploidentical	100 days	7	0	0% (0/7)
Not in Complete Remission	Haploidentical	365 days	7	1	14.3% (1/7)
Not in Complete Remission	MUD	30 days	2	0	0% (0/2)
Not in Complete Remission	MUD	100 days	3	0	0% (0/3)
Not in Complete Remission	MUD	365 days	2	1	50% (1/2)
Not in Complete Remission	MMUD	30 days	1	0	0% (0/1)
Not in Complete Remission	MMUD	100 days	1	0	0% (0/1)
Not in Complete Remission	MMUD	365 days	0	NA	NA% (NA/0)

7.4 TRM by Donor Type and CR Status (All Timepoints)

Table 20: Table 17A: TRM by Donor Type and Disease Status (30, 100, 365 days)

CR Status	Donor Type	Timepoint	N	TRM Events	TRM Rate (n)
Complete Remission	Sibling HLA-identical	30 days	1	0	0% (0/1)
Complete Remission	Sibling HLA-identical	100 days	1	0	0% (0/1)
Complete Remission	Sibling HLA-identical	365 days	2	0	0% (0/2)
Complete Remission	Haploidentical	30 days	7	0	0% (0/7)
Complete Remission	Haploidentical	100 days	5	0	0% (0/5)
Complete Remission	Haploidentical	365 days	5	1	20% (1/5)
Complete Remission	MUD	30 days	10	0	0% (0/10)
Complete Remission	MUD	100 days	8	0	0% (0/8)
Complete Remission	MUD	365 days	3	0	0% (0/3)
Complete Remission	MMUD	30 days	5	0	0% (0/5)
Complete Remission	MMUD	100 days	2	0	0% (0/2)
Complete Remission	MMUD	365 days	1	0	0% (0/1)
Not in Complete Remission	Sibling HLA-identical	30 days	2	0	0% (0/2)
Not in Complete Remission	Sibling HLA-identical	100 days	2	0	0% (0/2)
Not in Complete Remission	Sibling HLA-identical	365 days	0	NA	NA% (NA/0)
Not in Complete Remission	Haploidentical	30 days	2	0	0% (0/2)
Not in Complete Remission	Haploidentical	100 days	7	0	0% (0/7)
Not in Complete Remission	Haploidentical	365 days	7	2	28.6% (2/7)
Not in Complete Remission	MUD	30 days	2	0	0% (0/2)
Not in Complete Remission	MUD	100 days	3	0	0% (0/3)
Not in Complete Remission	MUD	365 days	2	0	0% (0/2)
Not in Complete Remission	MMUD	30 days	1	0	0% (0/1)
Not in Complete Remission	MMUD	100 days	1	0	0% (0/1)
Not in Complete Remission	MMUD	365 days	0	NA	NA% (NA/0)

7.5 Acute GVHD by Donor Type and CR Status (100 days)

Table 21: Table 19: 100-Day Acute GVHD II-IV by Donor Type and Disease Status

Disease Status	Donor Type	Cohort Size	Events	AGVHD II-IV Rate
Complete Remission				
Complete Remission	Sibling HLA-identical	1	0	0% (0/1)
Complete Remission	Haploididential	5	2	40% (2/5)
Complete Remission	MUD	8	1	12.5% (1/8)
Complete Remission	MMUD	2	1	50% (1/2)
Not in Complete Remission				
Not in Complete Remission	Sibling HLA-identical	2	0	0% (0/2)
Not in Complete Remission	Haploididental	7	2	28.6% (2/7)
Not in Complete Remission	MUD	3	0	0% (0/3)
Not in Complete Remission	MMUD	1	0	0% (0/1)

7.5 Chronic GVHD by Donor Type and CR Status (365 days)

Chronic GVHD (Any) by Donor Type and CR Status

Table 22: Table 20: Chronic GVHD (Any) by Donor Type and Complete Remission Status - Cumulative 2025

CR Status	Donor Type	N	Events	Chronic GVHD (Any) Rate (n/N %)
Complete Remission				
Complete Remission	Sibling HLA-identical	2	0	0% (0/2)
Complete Remission	Haploididential	5	0	0% (0/5)
Complete Remission	MUD	3	1	33.3% (1/3)
Complete Remission	MMUD	1	1	100% (1/1)
Not in Complete Remission				
Not in Complete Remission	Haploididental	7	0	0% (0/7)
Not in Complete Remission	MUD	2	0	0% (0/2)

Chronic GVHD (Moderate-Severe) by Donor Type and CR Status

Table 23: Table 21: Chronic GVHD (Moderate-Severe) by Donor Type and Complete Remission Status - Cumulative 2025

CR Status	Donor Type	N	Events	Chronic GVHD (Mod-Severe) Rate (%)
Complete Remission				
Complete Remission	Sibling HLA-identical	2	0	0% (0/2)
Complete Remission	Haploidentical	5	0	0% (0/5)
Complete Remission	MUD	3	1	33.3% (1/3)
Complete Remission	MMUD	1	0	0% (0/1)
Not in Complete Remission				
Not in Complete Remission	Haploidentical	7	0	0% (0/7)
Not in Complete Remission	MUD	2	0	0% (0/2)

Methodology

Cumulative Rolling Cohort Selection

Table 24: Table 12: Cumulative Rolling Cohort Selection Methodology

Milestone	Milestone Date Range	HSCT Date Range	Cohort Size
30 days	Jan 1, 2025 - Nov 30, 2025	Sep 1, 2024 - Oct 31, 2025	30
100 days	Jan 1, 2025 - Sep 30, 2025	Jul 1, 2024 - Sep 30, 2025	29
365 days	Jan 1, 2024 - Dec 31, 2025	Jan 1, 2024 - Dec 31, 2024	20

Key Definitions

TRM (Treatment-Related Mortality): Deaths directly attributed to the transplant procedure and immediate complications

NRM (Non-Relapse Mortality): Deaths from transplant-related complications (infection, GVHD, organ toxicity, other), excluding disease relapse/progression and TRM

RRM (Relapse-Related Mortality): Deaths from disease progression or relapse

Cumulative Rolling Cohort: Patients selected based on when they REACHED the milestone during the specified date range, ensuring adequate follow-up time for outcome assessment

Cumulative Mortality: Mortality percentages are cumulative and should increase at later timepoints (30d 100d 365d) as mortality accrues over time

Conclusions

Key Findings

1. **Overall mortality at 365 days:** 35%
 2. **Cumulative mortality progression:** 30d = 0% → 100d = 3.4% → 365d = 35%
 3. **Mortality breakdown at 365 days:** TRM = 15%, NRM = 10%, RRM = 10%
 4. **Disease status matters:** CR patients have better outcomes at all timepoints
 5. **GVHD challenges:** Haploidentical transplants show 33.3% acute GVHD II-IV
-

Report generated January 23, 2026 using cumulative rolling cohort methodology per JACIE Italian guidelines

TRM = Treatment-Related Mortality; NRM = Non-Relapse Mortality; RRM = Relapse-Related Mortality